Enveric Biosciences Announces First Quarter 2026 Financial Results and Business Update
Enveric Biosciences Reports First Quarter 2026 Results and Advances Non-Hallucinogenic Neuroplastogen Pipeline Enveric Biosciences reported financial results for the first quarter ended March 31, 2026, while also providing an extensive…
Kraken Regen Unveils Next-Generation Collagen Hydrogel for Regenerative Medicine Research
Kraken Regen Launches Advanced Collagen Platform Technology to Support Regenerative Medicine Research Kraken Regen has announced the launch of its new Collagen Platform Technology, introducing a high-purity collagen biomaterial engineered…
Sensei Biotherapeutics Reports Q1 2026 Financial Results and Highlights Corporate Progress
Sensei Biotherapeutics Advances PIKTOR Oncology Program Following Faeth Acquisition and $200 Million Financing Sensei Biotherapeutics reported its financial results for the first quarter ended March 31, 2026, while also outlining…
Kariya and NeuraLight Partner to Evaluate Brain Effects of Next-Generation GLP-1 Therapies
Kariya and NeuraLight Collaborate to Evaluate Brain Effects of Next-Generation GLP-1 Therapies Kariya Pharmaceuticals and NeuraLight have announced a strategic partnership aimed at advancing the development of next-generation brain-focused GLP-1…
Glooko Receives FDA 510(k) Clearance for EndoTool IV Cloud System
Glooko Receives FDA 510(k) Clearance for EndoTool IV Cloud Platform Glooko, Inc., a global digital health company specializing in diabetes management and glycemic safety solutions, has announced that the U.S.…
Worldwide Clinical Trials Expands Leadership Team to Advance Global Growth and Therapeutic Expertise
Worldwide Clinical Trials Expands Leadership Team to Enhance Global Reach and Therapeutic Expertise Worldwide Clinical Trials, a global contract research organization (CRO) focused on delivering specialized clinical development services for…
Affinia Therapeutics Showcases AFTX-201 Cardiomyopathy Data and AAV Platform Advances at ASGCT 2026
Affinia Therapeutics Highlights Advances in Gene Therapy Pipeline and Manufacturing at ASGCT 2026 Affinia Therapeutics showcased major progress across its cardiovascular and central nervous system gene therapy programs during multiple…
Ionis Pharmaceuticals Partner Biogen Reports Positive Phase 2 Results for Diranersen in Early Alzheimer’s Disease
Ionis and Biogen Report Promising Phase 2 Results for Tau-Targeting Alzheimer’s Therapy Diranersen Ionis Pharmaceuticals and Biogen have announced encouraging topline findings from the Phase 2 CELIA clinical study evaluating…
Adicet Bio Announces First Quarter 2026 Financial Results and Corporate Progress Updates
Adicet Bio Announces First Quarter 2026 Financial Results and Corporate Progress Updates Adicet Bio has reported financial results and operational progress for the first quarter ended March 31, 2026, highlighting…
Next Health Opens New Peoria Location Offering Advanced Longevity and Preventive Care Services in Arizona
Next Health Opens New Peoria Location Offering Advanced Longevity and Preventive Care Services in Arizona Next Health, a provider of preventive wellness, longevity, and personalized health optimization services, has announced…
Heart Failure 2026 Data Highlight Vutrisiran’s Strong Benefits Across ATTR-CM Patient Groups
New Heart Failure 2026 Analyses Highlight Consistent Clinical Benefits of Vutrisiran Across Diverse ATTR-CM Patient Groups Alnylam Pharmaceuticals has announced new analyses from its Phase 3 HELIOS-B clinical trial evaluating…
U.S. FDA Approves BeOne Medicines’ BEQALZI™ as First BCL2 Inhibitor for Relapsed or Refractory Mantle Cell Lymphoma
BeOne Medicines’ BEQALZI™ Receives U.S. FDA Approval as First BCL2 Inhibitor for Relapsed or Refractory Mantle Cell Lymphoma BeOne Medicines has announced that the U.S. Food and Drug Administration has…